The commensal consortium of the gut microbiome is associated with favorable responses to anti-programmed death protein 1 (PD-1) therapy in thoracic neoplasms.
The commensal consortium of the gut microbiome is associated with favorable responses to anti-programmed death protein 1 (PD-1) therapy in thoracic neoplasms.
复制标题
肠道微生物群的共生群与胸部肿瘤中抗程序性死亡蛋白 1 (PD-1) 治疗的良好反应相关。
DOI：
10.20892/j.issn.2095-3941.2020.0450
复制
发表时间：
2021-05-07
影响因子：
5.5
通讯作者：
Wang Y
中科院分区：
文献类型：
--
作者：
Yin H;Yang L;Peng G;Yang K;Mi Y;Hu X;Hao X;Jiao Y;Wang X;Wang Y
免疫检查点抑制剂已经彻底改变了多种类型实体瘤的癌症治疗，但正如预期的那样，很大一部分患者没有表现出持久的反应。因此，迫切需要能够在诊断时预测对免疫疗法的临床反应的生物标志物。在此，我们确定了抗程序性死亡蛋白1（PD-1）治疗期间基线肠道微生物与胸部肿瘤患者临床治疗效率之间的相关性。42例接受抗PD-1治疗的晚期胸部癌患者入组研究。使用16S核糖体RNA基因测序分析基线和时间序列粪便样本。肿瘤缓解、患者无进展生存期和总生存期用于衡量临床结局。应答者（n = 23）和无应答者（n = 19）之间的基线肠道微生物群的分布相似。应答组中阿克曼氏菌科、肠球菌科、肠杆菌科、肉杆菌科和梭菌科XI细菌家族的相对丰度显著较高。这5个细菌家族作为一个共同体，根据临床反应更好地对患者进行分层（P = 0.014）。肠道微生物丰度较高的患者PFS延长（P = 0.00016）。使用多变量分析，将唾液酸聚生体的丰度确定为胸部肿瘤中抗PD-1免疫治疗的独立预测因子（风险比：0.17; 95%置信区间：0.05 - 0.55; P = 0.003）。基线肠道微生物群可能对胸部肿瘤的抗PD-1治疗产生关键影响。诊断时肠道微生物的丰度可能有助于早期预测抗PD-1免疫治疗反应。
Immune checkpoint inhibitors have revolutionized cancer therapy for multiple types of solid tumors, but as expected, a large percentage of patients do not show durable responses. Biomarkers that can predict clinical responses to immunotherapies at diagnosis are therefore urgently needed. Herein, we determined the associations between baseline gut commensal microbes and the clinical treatment efficiencies of patients with thoracic neoplasms during anti-programmed death protein 1 (PD-1) therapy. Forty-two patients with advanced thoracic carcinoma who received anti-PD-1 treatment were enrolled in the study. Baseline and time-serial stool samples were analyzed using 16S ribosomal RNA gene sequencing. Tumor responses, patient progression-free survival, and overall survival were used to measure clinical outcomes. The diversities of the baseline gut microbiota were similar between responders (n = 23) and nonresponders (n = 19). The relative abundances of the Akkermansiaceae, Enterococcaceae, Enterobacteriaceae, Carnobacteriaceae and Clostridiales Family XI bacterial families were significantly higher in the responder group. These 5 bacterial families acted as a commensal consortium and better stratified patients according to clinical responses (P = 0.014). Patients with a higher abundance of commensal microbes had prolonged PFS (P = 0.00016). Using multivariable analysis, the abundance of the commensal consortium was identified as an independent predictor of anti-PD-1 immunotherapy in thoracic neoplasms (hazard ratio: 0.17; 95% confidence interval: 0.05–0.55; P = 0.003). Baseline gut microbiota may have a critical impact on anti-PD-1 treatment in thoracic neoplasms. The abundance of gut commensal microbes at diagnosis might be useful for the early prediction of anti-PD-1 immunotherapy responses.
登录
查看更多内容
影响因子：
3.7
作者：
Dowd SE;Wolcott RD;Sun Y;McKeehan T;Smith E;Rhoads D
通讯作者：
Rhoads D
影响因子：
7.5
作者：
Liu, Xinyan;Wu, Shucai;Hou, Zhihua
通讯作者：
Hou, Zhihua
影响因子：
45.3
作者：
Horn, Leora;Spigel, David R.;Eberhardt, Wilfried E. E.
通讯作者：
Eberhardt, Wilfried E. E.
影响因子：
56.9
作者：
Gill, Steven R.;Pop, Mihai;Nelson, Karen E.
通讯作者：
Nelson, Karen E.
DOI：
10.1099/00207713-51-4-1521
发表时间：
2001-07-01
影响因子：
2.8
作者：
Ezaki, T;Kawamura, Y;Shu, SE
通讯作者：
Shu, SE